Purpose: To evaluate the safety and feasibility of topical anesthesia in vitrectomy using the transconjunctival sutureless 25-gauge system (TSV 25G). Methods: TSV 25G vitrectomy was performed prospectively in 46 eyes of 46 patients with macular-based disorders, including macular holes (n = 31), idiopathic epiretinal membranes (n = 11), and vitreoretinal traction syndrome (n = 4). Topical anesthesia was administered in each patient by instilling 2% Alcaine at 5 min intervals, three times before surgery. Additional Alcaine drops were given as a supplementation if needed during the operation. The levels of intraoperative analgesia were graded from 1 (adequate) to 3 (inadequate). Results: Thirty-one patients (67.4%) tolerated the procedure well, with no additional anesthetic agent. Thirteen patients (28.3%) required additional topical anesthesia and 2 patients (4.3%) required a systemic sedative. Intraoperative pain occurred when the sclera was pierced by the microcannula and when sclera indentation was performed. No patient required additional retrobulbar or peribulbar anesthesia. There was no intraoperative complication which was specifically related to topical anesthesia. Conclusion: Topical anesthesia permits the successful management of some surgically less complex vitreoretinal disorders when the TSV 25G is used.

Costen MT, Newsom RS, Wainwright AC, et al: Expanding role of local anaesthesia in vitreoretinal surgery. Eye 2005;19:755–761.
Lai MM, Lai JC, Lee WH, et al: Comparison of retrobulbar and sub-Tenon’s capsule injection of local anesthetic in vitreoretinal surgery. Ophthalmology 2005;112:574–579.
Hay A, Flynn HW Jr, Hoffman JI, et al: Needle penetration of the globe during retrobulbar and peribulbar injections.Ophthalmology 1991;98:1017–1024.
Fujii GY, De Juan E Jr, Humayun MS, et al: A new 25-gauge instrument system for transconjunctival sutureless vitrectomy surgery. Ophthalmology 2002;109:1807–1812.
Ibarra MS, Hermel M, Prenner JL, et al: Longer-term outcomes of transconjunctival sutureless 25-gauge vitrectomy. Am J Ophthalmol 2005;139:831–836.
Fujii GY, De Juan E Jr, Humayun MS, et al: Initial experience using the transconjunctival sutureless vitrectomy system for vitreoretinal surgery. Ophthalmology 2002;109:1814–1820.
Bardocci A, Lofoco G, Perdicaro S, et al: Lidocaine 2% gel versus lidocaine 4% unpreserved drops for topical anesthesia in cataract surgery: a randomized controlled trial. Ophthalmology 2003;110:144–149.
Cagini C, Sbordone GB, Ricci AL, et al: Efficacy and safety of limbal anaesthesia for clear cornea phacoemulsification. Acta Ophthalmol Scand 2004;82:315–316.
Yepez JB, Cedeno de Yepez J, et al: Topical anesthesia in posterior vitrectomy Retina 2000;20:41–45.
Yepez JB, de Yepez JC, Azar-Arevalo O, et al: Topical anesthesia with sedation in phacoemulsification and intraocular lens implantation combined with 2-port pars plana vitrectomy in 105 consecutive cases. Ophthalmic Surg Lasers 2002;33:293–297.
Aras C, Ozdamar A, Yolar M, et al: Topical anesthesia in posterior vitrectomy. Retina 2000;20:566–567.
Chan WM, Loo AV, Tam BS: Topical anesthesia in posterior vitrectomy. Retina 2000;20:563–565.
Hilton GF, Josephberg RG, Halperin LS, et al: Office-based sutureless transconjunctival pars plana vitrectomy. Retina 2002:22:725–732.
Kwok AK, Lee YW, Lam DS: Topical anesthesia in posterior vitrectomy. Retina 2000;20:565–566.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.